Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Monday it got the final go-ahead from authorities to market its long-acting diabetes drug Tresiba in Europe.
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy